These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36468994)

  • 1. [Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease].
    Shamkhalova MS; Sukhareva OY; Shestakova MV
    Ter Arkh; 2022 Nov; 94(10):1188-1196. PubMed ID: 36468994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape.
    Mende CW
    Adv Ther; 2022 Jan; 39(1):148-164. PubMed ID: 34846711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DAPA-CKD: Significant Victory for CKD with or without Diabetes.
    Patel AB; Mistry K; Verma A
    Trends Endocrinol Metab; 2021 Jun; 32(6):335-337. PubMed ID: 33676827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease.
    Mima A
    Adv Ther; 2021 May; 38(5):2201-2212. PubMed ID: 33860925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
    Chertow GM; Vart P; Jongs N; Toto RD; Gorriz JL; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefánsson BV; Langkilde AM; Wheeler DC; Heerspink HJL;
    J Am Soc Nephrol; 2021 Sep; 32(9):2352-2361. PubMed ID: 34272327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
    Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
    Waijer SW; Vart P; Cherney DZI; Chertow GM; Jongs N; Langkilde AM; Mann JFE; Mosenzon O; McMurray JJV; Rossing P; Correa-Rotter R; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL
    Diabetologia; 2022 Jul; 65(7):1085-1097. PubMed ID: 35445820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of SGLT-2 inhibitors in the treatment of chronic kidney disease : Clinical and practical implications.
    Säemann M; Cejka D; Schmaldienst S; Rosenkranz AR; Mayer G
    Wien Klin Wochenschr; 2023 Feb; 135(3-4):97-109. PubMed ID: 36251099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The dapagliflozin and prevention of adverse outcomes in chronic kidney disease: results of the DAPA-CKD study].
    Batyushin MM
    Ter Arkh; 2021 Jun; 93(6):713-723. PubMed ID: 36286839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical and practical management of sodium-glucose cotransporter type 2 inhibitors in patients with chronic kidney disease].
    Castillo Moraga MJ; Turégano-Yedro M; Pallarés-Carratala V
    Semergen; 2023 Jun; 49 Suppl 1():102020. PubMed ID: 37355299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease.
    Del Vecchio L; Beretta A; Jovane C; Peiti S; Genovesi S
    Drugs; 2021 Sep; 81(13):1491-1511. PubMed ID: 34363606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on dapagliflozin for chronic kidney disease.
    Kelly MS
    Drugs Today (Barc); 2022 Feb; 58(2):69-75. PubMed ID: 35188141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.
    Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
    Diabetes Obes Metab; 2022 Nov; 24(11):2138-2147. PubMed ID: 35676798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes mellitus on cardiovascular and renal outcomes: A systematic review and meta-analysis.
    Reyes-Farias CI; Reategui-Diaz M; Romani-Romani F; Prokop L
    PLoS One; 2023; 18(11):e0295059. PubMed ID: 38019892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun.
    Sarafidis P; Ortiz A; Ferro CJ; Halimi JM; Kreutz R; Mallamaci F; Mancia G; Wanner C;
    J Hypertens; 2021 Jun; 39(6):1090-1097. PubMed ID: 33443971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.
    Wheeler DC; Jongs N; Stefansson BV; Chertow GM; Greene T; Hou FF; Langkilde AM; McMurray JJV; Rossing P; Nowicki M; Wittmann I; Correa-Rotter R; Sjöström CD; Toto RD; Heerspink HJL;
    Nephrol Dial Transplant; 2022 Aug; 37(9):1647-1656. PubMed ID: 34850160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin for the treatment of chronic kidney disease.
    Kurata Y; Nangaku M
    Expert Rev Endocrinol Metab; 2022 Jul; 17(4):275-291. PubMed ID: 35822873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.